Calculation
ROA | = | 100 | × | Net income (loss) attributable to Gilead1 | ÷ | Total assets1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2023 | 9.12% | = | 100 | × | 5,665) | ÷ | 62,125) |
Dec 31, 2022 | 7.27% | = | 100 | × | 4,592) | ÷ | 63,171) |
Dec 31, 2021 | 9.16% | = | 100 | × | 6,225) | ÷ | 67,952) |
Dec 31, 2020 | 0.18% | = | 100 | × | 123) | ÷ | 68,407) |
Dec 31, 2019 | 8.74% | = | 100 | × | 5,386) | ÷ | 61,627) |
Dec 31, 2018 | 8.57% | = | 100 | × | 5,455) | ÷ | 63,675) |
Dec 31, 2017 | 6.58% | = | 100 | × | 4,628) | ÷ | 70,283) |
Dec 31, 2016 | 23.70% | = | 100 | × | 13,501) | ÷ | 56,977) |
Dec 31, 2015 | 34.93% | = | 100 | × | 18,108) | ÷ | 51,839) |
Dec 31, 2014 | 34.91% | = | 100 | × | 12,101) | ÷ | 34,664) |
Dec 31, 2013 | 13.67% | = | 100 | × | 3,075) | ÷ | 22,497) |
Dec 31, 2012 | 12.20% | = | 100 | × | 2,592) | ÷ | 21,240) |
Dec 31, 2011 | 16.20% | = | 100 | × | 2,804) | ÷ | 17,303) |
Dec 31, 2010 | 25.03% | = | 100 | × | 2,901) | ÷ | 11,593) |
Dec 31, 2009 | 27.18% | = | 100 | × | 2,636) | ÷ | 9,699) |
Dec 31, 2008 | 28.65% | = | 100 | × | 2,011) | ÷ | 7,019) |
Dec 31, 2007 | 27.68% | = | 100 | × | 1,615) | ÷ | 5,835) |
Dec 31, 2006 | -29.12% | = | 100 | × | (1,190) | ÷ | 4,086) |
Dec 31, 2005 | 21.62% | = | 100 | × | 814) | ÷ | 3,765) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
Comparison to Competitors
Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2023 | 9.12% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 20.98% | 0.34% | -25.58% | 0.94% | 11.95% | 6.07% |
Dec 31, 2022 | 7.27% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 9.57% | 13.30% | 32.34% | 15.91% | 14.85% | 7.15% |
Dec 31, 2021 | 9.16% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 11.47% | 12.35% | 49.46% | 12.11% | 31.75% | 8.12% |
Dec 31, 2020 | 0.18% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 8.41% | 7.72% | -10.18% | 6.23% | 20.47% | 9.23% |
Dec 31, 2019 | 8.74% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 9.59% | 11.66% | -32.34% | 9.72% | 14.29% | 6.33% |
Dec 31, 2018 | 8.57% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 10.00% | 7.53% | -19.61% | 7.00% | 20.83% | 5.22% |
Dec 31, 2017 | 6.58% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 0.83% | 2.72% | — | 12.40% | 13.67% | 3.93% |
Dec 31, 2016 | 23.70% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 11.71% | 4.11% | — | 4.20% | 12.84% | 4.40% |
Dec 31, 2015 | 34.93% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 11.55% | 4.36% | — | 4.16% | 11.34% | 4.83% |
Dec 31, 2014 | 34.91% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 12.45% | 12.12% | — | 5.40% | 8.99% | 4.42% |
Dec 31, 2013 | 13.67% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 10.42% | 4.17% | — | 12.78% | 14.38% | 4.00% |
Dec 31, 2012 | 12.20% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 8.94% | 5.81% | — | 7.84% | 36.06% | 4.29% |
Dec 31, 2011 | 16.20% | — | 7.54% | 11.25% | 7.25% | 12.92% | 8.51% | 5.97% | — | 5.32% | -16.75% | 4.96% |
Dec 31, 2010 | 25.03% | — | 10.64% | 9.98% | 8.07% | 16.35% | 12.96% | 0.81% | — | 4.23% | -9.59% | 4.85% |
Dec 31, 2009 | 27.18% | — | 11.62% | 34.22% | 5.88% | 15.76% | 12.95% | 11.51% | — | 4.05% | -9.15% | 3.93% |
Dec 31, 2008 | 28.65% | — | 11.51% | 17.76% | 7.53% | -7.09% | 15.25% | 16.54% | — | 7.29% | -12.34% | 4.71% |
Dec 31, 2007 | 27.68% | — | 9.14% | 8.27% | 7.84% | 11.02% | 13.06% | 6.77% | — | 7.07% | -11.28% | 3.59% |
Dec 31, 2006 | -29.12% | — | 8.73% | 6.20% | 8.72% | 12.13% | 15.67% | 9.95% | — | 16.84% | -17.49% | 0.79% |
Dec 31, 2005 | 21.62% | — | 12.54% | 10.66% | 9.80% | 8.05% | 17.94% | 10.33% | — | 6.88% | -22.54% | 5.25% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Gilead Sciences Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Gilead Sciences Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2023 | 9.12% | 6.57% |
Dec 31, 2022 | 7.27% | 11.04% |
Dec 31, 2021 | 9.16% | 11.19% |
Dec 31, 2020 | 0.18% | 5.14% |
Dec 31, 2019 | 8.74% | 8.90% |
Dec 31, 2018 | 8.57% | 8.71% |
Dec 31, 2017 | 6.58% | 5.27% |
Dec 31, 2016 | 23.70% | 8.66% |
Dec 31, 2015 | 34.93% | 9.03% |
Dec 31, 2014 | 34.91% | 9.59% |
Dec 31, 2013 | 13.67% | 9.55% |
Dec 31, 2012 | 12.20% | 8.35% |
Dec 31, 2011 | 16.20% | 7.32% |
Dec 31, 2010 | 25.03% | 7.23% |
Dec 31, 2009 | 27.18% | 10.17% |
Dec 31, 2008 | 28.65% | 10.52% |
Dec 31, 2007 | 27.68% | 8.98% |
Dec 31, 2006 | -29.12% | 12.00% |
Dec 31, 2005 | 21.62% | 10.50% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Gilead Sciences Inc. | Health Care | |
---|---|---|
Dec 31, 2023 | 9.12% | 6.08% |
Dec 31, 2022 | 7.27% | 8.60% |
Dec 31, 2021 | 9.16% | 8.69% |
Dec 31, 2020 | 0.18% | 5.36% |
Dec 31, 2019 | 8.74% | 7.15% |
Dec 31, 2018 | 8.57% | 6.08% |
Dec 31, 2017 | 6.58% | 5.31% |
Dec 31, 2016 | 23.70% | 6.93% |
Dec 31, 2015 | 34.93% | 7.37% |
Dec 31, 2014 | 34.91% | 8.18% |
Dec 31, 2013 | 13.67% | 8.29% |
Dec 31, 2012 | 12.20% | 7.68% |
Dec 31, 2011 | 16.20% | 7.00% |
Dec 31, 2010 | 25.03% | 6.99% |
Dec 31, 2009 | 27.18% | 9.19% |
Dec 31, 2008 | 28.65% | 8.56% |
Dec 31, 2007 | 27.68% | 8.18% |
Dec 31, 2006 | -29.12% | 9.77% |
Dec 31, 2005 | 21.62% | 9.09% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).